Interventional psychiatry: the elephants in the room

The term “interventional psychiatry” has been coined to subsume interventions that are more procedural or invasive than standard pharmacological or psychotherapeutic treatments. Though originally proposed for brain stimulation techniques such as electroconvulsive therapy,¹ interventional psychiatry also extends to surgical procedures (e.g., circuit-based neurosurgery for intractable obsessive-compulsive disorder²), novel pharmacological interventions (e.g., ketamine or esketamine), enhanced psychotherapy approaches (e.g., psychedelic-assisted psychotherapy), or complex digital interventions (e.g., cognitive control training combined with non-invasive brain stimulation). Whereas the field of brain stimulation with its substantial array of techniques, including recent developments such as temporal interference stimulation³ and focused ultrasound,⁴ has been systematically established over decades,⁵ the inclusion of many other novel interventions is making it a very rapidly growing field of innovation.

Some of these interventions have excellent personalization potential, e.g., by including multimodal information on individual brain connectivity.⁶ For instance, precision-oriented approaches that functionally target individual access points on the cortex using repetitive transcranial brain stimulation (rTMS) have been proposed as treatments for neuropsychiatric disorders. In major depressive disorder, this approach has focused on the connectivity between the left dorsolateral prefrontal cortex and the subgenual anterior cingulate cortex. Here, neuronavigated targeting can be combined with concurrent TMS/functional magnetic resonance imaging to identify the involvement of target brain areas and investigate the effects of therapeutic rTMS sessions on circuits and networks.⁷

A parallel approach focuses on both precision in timing and brain state control using closed-loop techniques. These methods can be applied in both non-invasive brain stimulation and deep brain stimulation. In a paradigmatic case study,⁸ a 36-year-old patient with highly treatment-resistant major depressive disorder first underwent stimulus-response mapping of emotional circuitry with stereoelectroencephalography electrodes for 10 days to identify targets in time and space, which were confirmed by subsequent multimodal assessment of connectivity in response to stimulation protocols. After stereoelectroencephalography biomarkers had been identified, a deep brain sensing and stimulation device was implanted and biomarker-driven closed-loop therapy was implemented. During the subsequent course of stimulation, the patient improved and finally reached remission after several months. Similarly, personalized closed-loop approaches have been proposed for non-invasive brain stimulation.⁹

Some interventions focus on accelerating the onset of therapeutic effects. Rapidly acting interventions like ketamine¹⁰ and potentially faster brain stimulation methods like accelerated rTMS¹¹ create hope for quicker response and even remission, a clearly desirable goal in clinical research. Similarly, the concept of enhanced psychotherapy suggests that standard psychotherapy is insufficient due to its generally slow effect onset. However, two recent studies, one that incorporated a higher density of treatment sessions in the initial phase of cognitive behavioral therapy¹² and another that added transcranial direct current stimulation to a cognitive behavioral therapy group therapy,¹³ failed to show better efficacy than control interventions.

A completely divergent direction from rapidly acting interventions is long-term treatment to support continuous improvement or even recovery. Implanted brain stimulation devices, e.g., the effects of vagus nerve stimulation or deep brain stimulation for major depressive disorder can be observed over a number of years. Although a randomized controlled trial found that the antidepressant effects of such devices were no better than placebo, vagus nerve stimulation has nevertheless been proposed as a treatment for major depressive disorder based on the outcomes of long-term studies, which have found beneficial effects over 5 years compared to treatment as usual.¹⁴ Thus, some researchers have argued that although the effects of this intervention are not immediate, they may be highly effective in the long run.

The multitude of therapeutic approaches in interventional psychiatry indeed comes with questions about randomized controlled trial designs and a debate about placebo controls. The strict criteria of evidence-based medicine have been evolving in the field of pharmacotherapy, with proof of a drug’s superiority over placebo being mandatory for clinical implementation. However, in psychotherapy research, true placebo controls are not feasible, and active control groups have now replaced waiting list controls. In the field of interventional psychiatry, comparator conditions are becoming increasingly complex, and single therapeutic approaches must create their own “as close to active as possible” parallel control interventions (e.g., sham non-invasive brain stimulation). A critical question is which control interventions can serve as comparators for unique interventions, e.g., the immediate effects of psychedelic treatment, which completely prevent blinding. To date, no evidence-based criteria have been defined for proof of efficacy when long-term placebo treatment cannot be ethically justified or for acute interventions that cannot be placebo controlled. For some interventions, such criteria must be developed in addition to those for standard randomized controlled trial or meta-analysis. For instance, the observation that a specific intervention leads to shorter hospitalizations and outpatient visits and restores global functioning could point to novel efficacy criteria.

Finally, “interventional psychiatry” creates an urgent need for expert consensus on pathways of clinical implementation (i.e., national guidelines or treatment algorithms). Some of these methods will attract particular attention, and occasionally promotion on economic grounds may play a major role, but patients and caregivers may also ask for single interventions. This makes it necessary to change teaching and training for clinicians, develop standards for interdisciplinary collaboration (e.g., between psychiatry and neurosurgery regarding deep brain stimulation), and determine, with public and patient involvement, which ethical criteria must be established and communicated.¹⁵

In sum, the field of interventional psychiatry has been living in a niche of mental health care for decades but is now rapidly evolving, providing new opportunities for effective and safe therapies. Each of these interventions represents a clinically challenging field that requires comprehensive translational research. Therefore, we need to understand and tame these methodological heavyweights to guarantee that they do not behave like elephants in a porcelain shop (Figure 1).

Figure 1
Personalized transcranial or deep brain stimulation, pharmacological interventions (e.g. ketamine or psychedelics), and cognitive behavioral therapy enhanced with pharmacological agents or brain stimulation are three examples of approaches in the growing field of interventional psychiatry.¹⁵

References

• ¹
  Williams NR, Taylor JJ, Snipes JM, Short EB, Kantor EM, George MS. Interventional psychiatry: how should psychiatric educators incorporate neuromodulation into training? Acad Psychiatry. 2014;38:168-76.
• ²
  Rasmussen SA, Goodman WK. The prefrontal cortex and neurosurgical treatment for intractable OCD. Neuropsychopharmacology. 2022;47:349-60.
• ³
  Grossman N, Okun MS, Boyden ES. Translating Temporal Interference Brain Stimulation to Treat Neurological and Psychiatric Conditions. JAMA Neurol. 2018;75:1307-8.
• ⁴
  Philip NS, Arulpragasam AR. Reaching for the unreachable: low intensity focused ultrasound for non-invasive deep brain stimulation. Neuropsychopharmacology. 2022 Jul 22. Epub ahead of print.
• ⁵
  Rosson S, Filippis R, Croatto G, Collantoni E, Pallottino S, Guinart D, et al. Brain stimulation and other biological non-pharmacological interventions in mental disorders:a umbrella review. Neurosci Biobehav Rev. 2022;139:104743.
• ⁶
  Padberg F, Bulubas L, Mizutani-Tiebel Y, Burkhardt G, Kranz GS, Koutsouleris N, et al. The intervention, the patient and the illness – personalizing non-invasive brain stimulation in psychiatry. Exp Neurol. 2021;341:113713.
• ⁷
  Mizutani-Tiebel Y, Tik M, Chang KY, Padberg F, Soldini A, Wilkinson Z, et al. Concurrent TMS-fMRI: technical challenges, developments, and overview of previous studies. Front Psychiatry. 2022;13:825205.
• ⁸
  Scangos KW, Khambhati AN, Daly PM, Makhoul GS, Sugrue LP, Zamanian H, et al. Closed-loop neuromodulation in an individual with treatment-resistant depression. Nat Med. 2021;27:1696-700.
• ⁹
  Zrenner B, Zrenner C, Gordon PC, Belardinelli P, McDermott EJ, Soekadar SR, et al. Brain oscillation-synchronized stimulation of the left dorsolateral prefrontal cortex in depression using real-time EEG-triggered TMS. Brain Stimul. 2020;13:197-205.
• ¹⁰
  Alnefeesi Y, Chen-Li D, Krane E, Jawad MY, Rodrigues NB, Ceban F, Di et al. Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & meta-analysis. J Psychiatr Res. 2022;151:693-709.
• ¹¹
  Cole EJ, Phillips AL, Bentzley BS, Stimpson KH, Nejad R, Barmak F, et al. Stanford neuromodulation therapy (SNT): a double-blind randomized controlled trial. Am J Psychiatry. 2022;179:132-41.
• ¹²
  Pittig A, Heinig I, Goerigk S, Thiel F, Hummel K, Scholl L, et al. Efficacy of temporally intensified exposure for anxiety disorders: a multicenter randomized clinical trial. Depress Anxiety. 2021;38:1169-81.
• ¹³
  Aust S, Brakemeier EL, Spies J, Herrera-Melendez AL, Kaiser T, Fallgatter A, et al. Efficacy of augmentation of cognitive behavioral therapy with transcranial direct current stimulation for depression: a randomized clinical trial. JAMA Psychiatry. 2022;79:528-37.
• ¹⁴
  Aaronson ST, Sears P, Ruvuna F, Bunker M, Conway CR, Dougherty DD, et al. A 5-year observational study of patients with treatment-resistant depression treated with vagus nerve stimulation or treatment as usual: comparison of response, remission, and suicidality. Am J Psychiatry. 2017;174:640-8.
• ¹⁵
  Giacobbe P, Ng E, Blumberger DM, Daskalakis ZJ, Downar J, Garcia C, et al. Interventional psychiatry: an idea whose time has come? Can J Psychiatry. 2021;66:316-8.

Publication Dates

• Publication in this collection
  25 Nov 2022
• Date of issue
  Nov-Dec 2022

History

• Received
  05 Aug 2022
• Accepted
  05 Aug 2022